Midsized biotechs press White House to drop CMS pricing rules

July 17, 2026 02:42 PM EDT PharmaFDA+ Mid­size biotechs take case against CM­S' GLOBE and GUARD mod­els to White House Max Bayer Senior Reporter A num­ber of mid­size biotech com­pa­nies have met with White House and HHS of­fi­cials in the last week, pre­sent­ing their case for why two pend­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER